Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 2/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.46 |
| ▸ | RELA | Q04206 | 2/20 | 0.46 |
| ▸ | FPR2 | P25090 | 11/20 | 0.43 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.38 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.38 |
| ▸ | PDE5A | O76074 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15942742 | 0.91 | NFKB1 (0.50) | NFKB1NFKB2RELAFPR2CYSLTR2 | |
| SCHEMBL18532079 | 0.88 | NFKB1 (0.61) | NFKB1NFKB2RELAFPR2PPARG | |
| SCHEMBL19008213 | 0.86 | FPR2 (0.50) | NFKB1NFKB2RELAFPR2 | |
| SCHEMBL13409715 | 0.80 | NFKB1 (0.46) | NFKB1NFKB2RELAFPR2CYSLTR2 | |
| SCHEMBL4547585 | 0.79 | NFKB1 (0.66) | NFKB1NFKB2RELAFPR2PPARG | |
| SCHEMBL589185 | 0.79 | NFKB1 (0.66) | NFKB1NFKB2RELAFPR2PPARG | |
| SCHEMBL4547582 | 0.79 | NFKB1 (0.66) | NFKB1NFKB2RELAFPR2PPARG | |
| SCHEMBL17402445 | 0.79 | NFKB1 (0.66) | NFKB1NFKB2RELAFPR2PPARG | |
| SCHEMBL589186 | 0.79 | NFKB1 (0.66) | NFKB1NFKB2RELAFPR2PPARG | |
| SCHEMBL15942746 | 0.79 | NFKB1 (0.66) | NFKB1NFKB2RELAFPR2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825271-B2 | Lipoxin compounds and their use in treating cell proliferative disorders | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7741369-B2 | Lipoxin compounds and their use in treating cell proliferative disorders | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-20090270498-A1 | Lipoxin Compounds and Their use in Treating Cell Proliferative Disorders | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090258945-A1 | Lipoxin Compounds and Their Use in Treating Cell Proliferative Disorders | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2009-10-15 | — | — | US | disclosed |
| US-7294728-B2 | Lipoxin compounds and their use in treating cell proliferative disorders | SERHAN CHARLES N | 2007-11-13 | — | — | US | disclosed |
| US-7288569-B2 | Lipoxin compounds and their use in treating cell proliferative disorders | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2007-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258945-A1 | Lipoxin Compounds and Their Use in Treating Cell Proliferative Disorders | ALOX15, ALOX12, ALOX15B | NFKB1 743/4885NFKB2 805/4885RELA 1937/4885 |
| US-20090270498-A1 | Lipoxin Compounds and Their use in Treating Cell Proliferative Disorders | ALOX15, ALOX12, ALOX15B | NFKB1 743/4885NFKB2 805/4885RELA 1937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.